AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04056702 — intervention group
Intervention type: DRUG
Intervention: Elexacaftor-tezacaftor-ivacaftor exposure
Description: Once a clinical decision has been made to prescribed a patient triple combination therapy, people with CF are eligible to participate in this study.
Study NCT03241706 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low Fructose
Description: IV fructose (1.3 mg/kg/min)
Study NCT03241706 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline given as a comparison to fructose.
Study NCT03241706 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Somatostatin
Description: IV infusion of somatostatin (60 ng/kg/min)
Study NCT03241706 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Somatostatin
Description: IV infusion of somatostatin (60 ng/kg/min)
Study NCT03241706 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: IV infusion of insulin between 20-60 mU/m2/min.
Study NCT03287726 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: probiotics
Description: NYCOPRO, a multistrain probiotic (7 strains of Lactobacilli and Bifidobacteria) sold in the Norwegian pharmacies. 2 capsules/day (one with lunch and one with dinner). 2 text messages daily as a reminder. Follow up meeting at ObeCe (St. Olavs hospital) every month with a research nurse, for weighing, blood pressure measurement and collection of probiotics dose for the following month.
Study NCT03287726 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo 2 capsules/day (one with lunch and one with dinner). 2 text messages daily as a reminder. Follow up meeting at ObeCe (St. Olavs hospital) every month with a research nurse, for weighing, blood pressure measurement and collection of probiotics dose for the following month.
Study NCT03241706 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Insulin
Description: IV infusion of insulin between 20-60 mU/m2/min.
Study NCT03241706 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucagon
Description: IV glucagon (0.65 ng/kg/min).
Study NCT03241706 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glucagon
Description: IV glucagon (0.65 ng/kg/min).
Study NCT03241706 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dextrose solution
Description: IV dextrose to clamp the plasma glucose at the desired level.
Study NCT03241706 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dextrose solution
Description: IV dextrose to clamp the plasma glucose at the desired level.
Study NCT03241706 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High Fructose
Description: IV-fructose (6.5 mg/kg/min)
Study NCT01982994 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education/Daily Planning
Description: In this study, we will use educational materials delivered at the initial enrollment session and in daily facts of the day presented electronically to heighten awareness of (1) the risks of insufficient physical activity and excessive sedentary behavior, and (2) the expected beneficial outcomes of increased physical activity and reduced sedentary behavior. These messages should are designed to increase intentions to engage in physical activity and to limit sedentary behavior (motivational phase)
Study NCT05093062 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Tian Jiu Therapy
Study NCT02735044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine,300 U/mL
Description: Subcutaneous injection in the morning or evening using a prefilled pen. Dose titration to achieve fasting self-monitored plasma glucose (SMPG) from 90 to 130 milligram/deciliter (mg/dL) (5.0 to 7.2 millimol per liter \[mmol/L\])
Study NCT02735044 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine (100 units /mL)
Description: Subcutaneous injection in the morning or evening using a prefilled pen. Dose titration to achieve fasting SMPG from 90 to 130 mg/dL (5.0 to 7.2 mmol/L)
Study NCT02735044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Background therapy
Description: Fast-acting mealtime insulin analogs
Study NCT03637114 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shamed Hypoxia (FiO2: 20.9)
Description: Inhalation of unmodified air through an altitude Simulator (Altitrainer) for approximately 1 hour given by a facemask
Study NCT00767637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanthanum Carbonate (BAY77-1931)
Description: BAY77-1931 750mg, in the morning, day and evening
Study NCT03009578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron Sucrose Injection
Description: iron Intramuscular injections
Study NCT03009578 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous Bisglycinate
Description: oral iron tablets
Study NCT00313378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypothetica
Study NCT00313378 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Hypothetica
Study NCT01647620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DPOC-4088
Description: A 10-day oral dosing of DPOC-4088 prolonged release tablet (20 hr release formulation). Starting dose in dose step 1 is 100 mg daily.
Study NCT01647620 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A 10-day oral dosing of matching placebo prolonged release tablet.
Study NCT03158116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Aztreonam
Description: Inhaled antibiotic with anti-pseudomonal properties
Study NCT02260700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911 (Treatment A)
Description: Participants will receive a single oral 25 mg dose of JNJ-54861911 as Treatment A (oral suspension formulation) under fasted conditions in one of the treatment periods.
Study NCT04579536 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Vanish White Varnish
Description: 5% Sodium Fluoride (NaF) with Tri-Calcium Phosphate topical varnish (Vanish White Varnish, 3M ESPE, Dental Products, St. Paul, MN, USA) will be used on 84 first permanent molars at baseline, 3, 6, 12 and 18 months.
Study NCT01180036 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: 1000 mg, I.V. on Days 1 and 15 and will be retreated at month 6 independent of cluster of differentiation (CD) 19+ B cell count
Study NCT01180036 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine
Description: Patients randomized to the Cyclosporine arm will be started at a dose of (CsA = 3.5 mg/kg/day p.o. divided into 2 doses for 12 months). Target trough CsA blood levels, as determined in whole blood by High Performance Liquid Chromatography (HPLC), are 125 to 175 ng/ml. A persistent and otherwise unexplained increase in serum creatinine >30% would prompt an approximate 25% dose reduction of CSA, aiming for a corresponding 25% reduction in CSA trough level. If with this dose reduction the creatinine does not return to within 30% of baseline levels within 3 weeks, then a second dose reduction of approximately 25% with similar reduction in CSA trough level will be used. If the creatinine does not fall to baseline values with this second dose reduction, the drug will be discontinued. At the end of 12 months, Cyclosporine will be tapered by 1/3 of the maintenance dose monthly and hence discontinued after 3 months.
Study NCT01404559 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ossur Variflex prosthetic foot
Description: Lightweight energy-storing prosthetic foot
Study NCT01404559 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ossur Ceterus prosthetic foot
Description: Shock-absorbing prosthetic foot
Study NCT01404559 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endolite Elite Blade prosthetic foot
Description: Multi-axial prosthetic foot
Study NCT03924219 — intervention group
Intervention type: OTHER
Intervention: CMV T cell Immunity Assay
Description: Flow cytometry based assay quantifying IFN-gamma expression in T cells following CMV peptide stimulation (Viracor)
Study NCT03549572 — intervention group
Intervention type: BEHAVIORAL
Intervention: Coma Recovery Scale-Revised
Description: Patients will be assessed using the CRS-R and the CRSR-FAST. The CRS-R is a standardized neurobehavioral rating scale that consists of 23 items organized into six subscales that address arousal, auditory, visual, motor, oromotor/verbal, and communication systems. Each subscale is organized hierarchically, with lower items representing reflexive behaviors and higher items indicative of cognitively-mediated behaviors. Reliability and validity have been demonstrated in multiple studies. The CRSR-FAST consists of 10 items organized into 4 subscales that address arousal, visual, motor and verbal/oromotor systems. Each subscale is organized hierarchically, with lower items representing reflexive behaviors and higher items indicative of cognitively-mediated behaviors.
Study NCT03625869 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PiCSO
Description: After blood flow restoration, the subjects meeting all inclusion and none exclusion criterial will be enrolled into the study and randomized either to PiCSO Group or Control Group. If the subject is randomized to PiCSO Group, the coronary sinus (CS) will be cannulated through the femoral vein and the PiCSO Impulse Catheter will be placed in the CS. Once PiCSO Impulse Catheter is placed into CS, PiCSO treatment is started followed by stenting. The physician shall target a PiCSO treatment of 45 minutes (at minimum 30 minutes) whereas the treatment should be continued during and post stent insertion, but should not exceed a maximum duration of 90 minutes. At the end of the PiCSO treatment, the PiCSO Impulse Console is stopped and the PiCSO Impulse Catheter is removed.
Study NCT02405247 — intervention group
Intervention type: OTHER
Intervention: Patient Reported Outcome (PRO)
Description: Exposure to Quality of Life Questionnaires (EORTC QLQ-LC13, EORTC QLQ-C30 and EQ-5D-5L) every 3 months during standard of care visits.
Study NCT02713984 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-HER2 CAR-T
Description: HER-2-targeting CAR-T cells infusion in HER2 positive cancers
Study NCT03636672 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: perturbation training
Description: perturbation training during stationary bicycle riding
Study NCT03636672 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: perturbation training
Description: perturbation training during stationary bicycle riding
Study NCT02323126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGF816
Description: EGF816 150 mg once daily (QD) administered orally as a capsule
Study NCT02323126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INC280
Description: INC280 400 mg twice daily (BID) administered orally as a tablet
Study NCT02323126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 3 mg/kg every 2 weeks (Q2W) administered by intravenous infusion
Study NCT01741233 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: VitDgen
Study NCT00858728 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 5 portions
Description: Subjects randomised to the intervention group will be provided with a selection of fruit and vegetables once a week (from a local supermarket) and will be asked to consume 5 portions of fruit and vegetables per day. For the purposes of this study, a portion will be as defined by the Food Standards Agency, i.e. an 80 g serving (one apple, orange or banana, or 3 heaped tablespoons of vegetables).
Study NCT00858728 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: 2 portions
Description: Subjects randomised to the control group will be provided with a selection of fruit and vegetables once a week (from a local supermarket) and will be asked to consume 2 portions of fruit and vegetables per day. For the purposes of this study, a portion will be as defined by the Food Standards Agency, i.e. an 80 g serving (one apple, orange or banana, or 3 heaped tablespoons of vegetables).
Study NCT01152593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mupirocin
Description: Intranasal cream given to patient after confirmation of colonization
Study NCT01168830 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AMS-3.0
Study NCT01066104 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Xolair placebo
Description: two to four weeks (dosage and frequency will be determined based on patient weight and IgE level)
Study NCT01066104 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xolair (omalizumab)
Description: two to four weeks (dosage and frequency will be determined based on patient weight and IgE level)
Study NCT04660552 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cognilum TM: Light Treatment Condition
Description: The children will wear the CognilumTM device for up to 15 minutes at a time, twice a week, for a period of 8 weeks.
Study NCT04660552 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Cognilum TM: Light Treatment Condition
Description: The children will wear the CognilumTM device for up to 15 minutes at a time, twice a week, for a period of 8 weeks.
Study NCT03928418 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-person counseling session
Description: Brief alcohol reduction counseling is provided by a trained counselor to the study participant at the HIV clinic during two sessions that are 3 months apart.
Study NCT03928418 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Live phone call booster session
Description: Brief alcohol reduction counseling booster sessions every 3 weeks delivered via a live phone call from a trained counselor to the study participant given within 3 months and in between two in-person counseling sessions.
Study NCT03928418 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technology (IVR or SMS) booster session
Description: Brief alcohol reduction counseling booster sessions once to twice a week delivered via a choice of interactive voice response (IVR) or short message service (SMS) phone technology to the study participant given within 3 months and in between two in-person counseling sessions.
Study NCT01399151 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D - Treatment 1
Description: Volunteers will take a 400 IU/day dose of Vitamin D for 12 weeks.
Study NCT01399151 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D - Treatment 2
Description: Volunteers will take a 2,000 IU/day dose of Vitamin D for 12 weeks.
Study NCT02260700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911 (Treatment B)
Description: Participants will receive a single oral 25 mg dose of JNJ-54861911 as Treatment B (solid formulation) under fasted conditions in one of the treatment periods.
Study NCT01399151 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D - Treatment 3
Description: Volunteers will take a 5,000 IU/day dose of Vitamin D for 12 weeks.
Study NCT03668470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dulaglutide
Description: Dulaglutide 1.5mg : One injection per week during 24 weeks
Study NCT03668470 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: one injection per week during 24 weeks
Study NCT02260700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911 (Treatment C)
Description: Participants will receive a single oral 25 mg dose of JNJ-54861911 as Treatment C (solid formulation) under fed conditions in one of the treatment periods.
Study NCT02735044 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Background therapy
Description: Fast-acting mealtime insulin analogs
Study NCT00387023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 250 mg/m\^2 IV over 4-6 hours for 2 weeks.
Study NCT00387023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zevalin
Description: 5 mCi/kg IV over 30 minutes for 1 week, followed by 0.3 mCi/kg or 0.4 mCi/kg 90Y-Zevalin based on platelet counts for 1 week.
Study NCT04322266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1701
Description: Ezetimibe / Rosuvastatin / Amlodipine / Losartan potassium
Study NCT04322266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1306
Description: Ezetimibe /Rosuvastatin
Study NCT00964002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: efavirenz
Study NCT01828606 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: coban 2 system
Description: All centres will perform the pressure measurements with Picopress, Microlab Elettronica, Italy For mobility measurements all centres will be supplied with pedometers. For perometry the centres will use their own equipment~According to protocol the materials are applied to the whole leg and the measuring devices are put in place
Study NCT01828606 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: coban lite system
Description: All centres will perform the pressure measurements with Picopress, Microlab Elettronica, Italy For mobility measurements all centres will be supplied with pedometers. For perometry the centres will use their own equipment~According to protocol the materials are applied to the whole leg and the measuring devices are put in place
Study NCT00487942 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: armodafinil
Description: 50 mg/day armodafinil
Study NCT00487942 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: armodafinil
Description: 100 mg/day armodafinil
Study NCT00487942 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: armodafinil
Description: 200 mg/day armodafinil
Study NCT00487942 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT04875377 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Reformulated pizza
Description: Reformulated food with 400ug of iodine per meal, three times per week (to achieve 122% of weekly recommended intakes - average 140ug/day).
Study NCT04875377 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control pizza
Description: Control (placebo) meal to consume thrice weekly (no iodine supplementation).
Study NCT04875377 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Seaweed capsule
Description: Capsules containing seaweed extract, the iodine-rich ingredient in the reformulated pizza, 400ug iodine per capsule, to be consumed three times per week (122% of weekly recommended intake).
Study NCT04875377 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control capsule
Description: Empty capsules (placebo)
Study NCT03263910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPO-11
Description: 20 ml NPO-11
Study NCT03263910 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 20 ml NPO-11(Placebo)
Study NCT01162824 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Acetylcholine
Description: Incremental doses of 2, 20 and 100 µg of ACH will be injected into the left coronary artery (LCA) via the diagnostic catheter for 3 minutes each. After that 80 µg of ACH will be injected into the right coronary artery. Coronary angiography will be performed after each 3 minute dose period. After the test or when intolerable chest pain due to coronary spasm occurs, 0.2 mg of glyceryltrinitrate will be injected into each vessel. During the test, heart rate, blood pressure and ECG will be monitored continuously.
Study NCT01162824 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Adenosine
Description: Coronary blood flow velocity measurements will be performed in the mid segment of the left anterior descending artery with a 0.014-in intracoronary Doppler guidewire connected to the corresponding interface. Measurements will be obtained after the administration of nitroglycerin, at baseline and during maximal hyperaemia. Sustained intravenous administration of adenosine - an arteriolar vasodilator- will be used to induce maximal hyperaemia (140-180µg/kg/min).
Study NCT01825512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferiprone
Description: Deferiprone 80 mg/mL oral solution
Study NCT01825512 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Deferasirox
Description: Deferasirox is used at the following dosage strengths: 125 mg, 250 mg and 500 mg
Study NCT02091362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2409021
Description: Administered orally
Study NCT02091362 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study NCT02091362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Administered as background therapy.
Study NCT02091362 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Administered as background therapy.
Study NCT04444986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FAVIR 200 MG FT
Description: FAVICOVIR containing 200 mg favipiravir manufactured by Kocak, Turkey.
Study NCT04444986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVIGAN 200 mg FT
Description: AVIGAN containing 200 mg favipiravir manufactured by Toyama, Japan